Own the gold standard ✨ in financial data & analytics
fair value · 20 million securities worldwide · 50 year history · 10 year estimates · leading business news

Subscribe for $2
Overview
Profile

SymBio Pharmaceuticals stock price, quote, forecast and news

4582.T
JP3383050006
A1JMJE

Price

237.00
Today +/-
-0.03
Today %
-1.67 %
P

SymBio Pharmaceuticals stock price

%
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the SymBio Pharmaceuticals stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the SymBio Pharmaceuticals stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the SymBio Pharmaceuticals stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze SymBio Pharmaceuticals's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

SymBio Pharmaceuticals Stock Price History

DateSymBio Pharmaceuticals Price
9/17/2024237.00 undefined
9/13/2024241.00 undefined
9/12/2024245.00 undefined
9/11/2024238.00 undefined
9/10/2024247.00 undefined
9/9/2024244.00 undefined
9/6/2024249.00 undefined
9/5/2024255.00 undefined
9/4/2024253.00 undefined
9/3/2024266.00 undefined
9/2/2024266.00 undefined
8/30/2024267.00 undefined
8/29/2024273.00 undefined
8/28/2024280.00 undefined
8/27/2024286.00 undefined
8/26/2024304.00 undefined
8/23/2024287.00 undefined
8/22/2024287.00 undefined
8/21/2024299.00 undefined
8/20/2024312.00 undefined

SymBio Pharmaceuticals Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into SymBio Pharmaceuticals, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by SymBio Pharmaceuticals from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects SymBio Pharmaceuticals’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of SymBio Pharmaceuticals. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into SymBio Pharmaceuticals’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing SymBio Pharmaceuticals’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on SymBio Pharmaceuticals’s growth potential.

SymBio Pharmaceuticals Revenue, EBIT and net profit per share

DateSymBio Pharmaceuticals RevenueSymBio Pharmaceuticals EBITSymBio Pharmaceuticals Net Income
2026e14.14 B undefined0 undefined2.88 B undefined
2025e13.81 B undefined0 undefined2.42 B undefined
2024e12.93 B undefined0 undefined2.05 B undefined
20235.59 B undefined-811.67 M undefined-1.96 B undefined
202210.01 B undefined1.96 B undefined1.18 B undefined
20218.26 B undefined1.02 B undefined2.03 B undefined
20202.99 B undefined-4.51 B undefined-4.09 B undefined
20192.84 B undefined-4.3 B undefined-4.38 B undefined
20183.84 B undefined-2.66 B undefined-2.75 B undefined
20173.44 B undefined-3.95 B undefined-3.98 B undefined
20162.37 B undefined-2.13 B undefined-2.31 B undefined
20151.93 B undefined-2.55 B undefined-2.63 B undefined
20141.96 B undefined-1.3 B undefined-1.12 B undefined
20131.53 B undefined-1.68 B undefined-1.61 B undefined
20121.96 B undefined-1.7 B undefined-1.73 B undefined
20111.88 B undefined-2.07 B undefined-2.1 B undefined
20101.45 B undefined-612.8 M undefined-642.3 M undefined
20091.19 B undefined-208 M undefined-217.9 M undefined
20081.63 B undefined132.9 M undefined21 M undefined
20070 undefined-1.33 B undefined-1.33 B undefined
20060 undefined-708 M undefined-711.2 M undefined

SymBio Pharmaceuticals Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)REVENUE GROWTH (%)GROSS MARGIN (%)GROSS INCOME (B)EBIT (B)EBIT MARGIN (%)NET INCOME (B)NET INCOME GROWTH (%)SHARES (M)DOCUMENTS
2006200720082009201020112012201320142015201620172018201920202021202220232024e2025e2026e
001.631.191.451.881.961.531.961.932.373.443.842.842.998.2610.015.5912.9313.8114.14
----26.9321.7529.793.88-21.6427.61-1.1322.5045.4411.35-26.025.29176.4021.22-44.15131.316.812.37
--100.00100.0083.52-52.0730.3320.7626.9130.1138.1829.9430.5630.4528.9970.2575.9378.92---
001.631.191.21-0.980.590.320.530.580.91.031.170.860.875.87.64.41000
-0.71-1.330.13-0.21-0.61-2.07-1.7-1.68-1.3-2.55-2.13-3.95-2.66-4.3-4.511.021.96-0.81000
--8.10-17.46-42.21-109.78-86.96-109.66-66.65-131.97-89.82-114.61-69.26-151.60-150.8512.3119.61-14.51---
-0.71-1.330.02-0.22-0.64-2.1-1.73-1.61-1.12-2.63-2.31-3.98-2.75-4.38-4.092.031.18-1.962.052.422.88
-86.50-101.58-1,133.33195.85227.73-17.63-7.39-30.53136.05-12.1271.94-30.8059.01-6.54-149.68-41.98-266.41-204.4917.9019.11
4.84.84.84.84.83.74.85.87.78.19.8312.4616.6323.1532.9538.8439.6139.9000
---------------------
Details

Keystats

ⓘ

Revenue and Growth

The SymBio Pharmaceuticals Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the SymBio Pharmaceuticals is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETSCASH BALANCE (B)RECEIVABLES (B)OTHER REC. (M)INVENTORIES (M)OTHER CURRENT LIAB. (M)CURRENT ASSETS (B)TANGIBLE ASSETS (M)LONG-T. INVEST. (M)LONG-T. REC. (M)INTANGIBLE ASSETS (M)GOODWILL (M)OTHER NON-CURRENT ASSETS (B)NON-CURRENT ASSETS (B)TOTAL ASSETS (B)LIABILITIESCOMMON STOCK (B)ADDITIONAL PAID-IN CAPITAL (B)RETAINED EARNINGS (M)OTHER EQUITY (k)UNREAL. GAINS/LOSSES (k)EQUITY (B)LIABILITIES (M)PROVISIONS (M)OTHER SHORT-TERM LIAB. (B)SHORT-TERM DEBTS (M)LONG-TERM DEBT PORTION (k)SHORT-TERM REC. (B)LONG-T. LIAB. (M)DEFERRED TAXES (M)OTHER LIAB. (M)LONG-T. LIABILITIES (M)DEBT (B)TOTAL CAPITAL (B)
200620072008200920102011201220132014201520162017201820192020202120222023
                                   
1.850.721.374.124.026.514.847.266.594.265.722.954.823.913.853.866.286.52
00000.010.160.1500.270.30.490.490.410.550.412.152.080.91
0009.1069.639.532.619.9034.7798.44124.86275.32314.76000
00000207.5164.9125.2245133.2273.39363.07534.410.64944.92385.68469.38232.03
54.215.190.188191.1227.7228.1212.7161.1131.4170.06138.08146.15151.42299.99354.54475.86420.4
1.90.741.464.224.217.185.427.637.294.836.694.046.044.895.826.759.318.08
9.58.613.313.421.917.413.710.550.253.5574.5246.8756.9575.4976.783.6369.010
000000000000000000
00000000000000314.76000
3.73.92.91.80.812.710.95.964.851.4141.9968.8871.38240.53301.84259.1222.20
000000000000000000
0.020.020.020.030.030.050.060.040.050.050.080.10.070.070.081.360.830.09
0.030.030.040.040.050.080.080.050.160.160.190.220.20.390.771.711.120.09
1.940.771.54.264.267.265.57.697.454.986.884.256.245.276.598.4510.438.17
                                   
1.531.581.893.383.716.026.028.068.338.339.9510.7612.9714.8717.0417.1617.5517.95
1.51.551.863.353.685.995.998.038.38.39.9210.7312.9414.8417.0217.1317.5217.93
-1,143.4-2,469.4-2,448.4-2,666.3-3,308.6-5,413.1-7,119.2-8,654.9-9,667.2-12,199.72-14,381.71-18,253.93-21,013.34-25,298.58-29,389.57-27,458.41-26,477.81-28,575.26
0000000000-10-101-1244-5,986
20000-6,5000-5000200-700000000000
1.890.671.314.054.086.614.97.436.964.435.483.244.94.424.676.838.597.3
00001.2309329.80306319.87321.86604.38726.1120.91665.4669.6846.630
0037.608.10000000000516.0400
0.060.120.160.210.170.340.270.250.180.230.620.410.610.750.950.931.880.96
000000000000000000
0000070070070070064200000000
0.060.120.190.210.180.650.60.250.490.550.941.011.340.871.621.521.920.96
000002.721.30.604500000000
000000000000000000
001.41.61.82.11.71.71.61.541.41.391.281.622.05189.213.393.71
001.41.61.84.83.732.21.54451.41.391.281.622.05189.213.393.71
0.060.120.190.210.180.650.60.250.490.551.391.011.340.871.621.711.930.96
1.950.791.54.264.267.265.57.697.454.986.884.256.245.296.298.5410.528.26
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of SymBio Pharmaceuticals provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand SymBio Pharmaceuticals's financial health and stability.

Assets

SymBio Pharmaceuticals's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that SymBio Pharmaceuticals must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of SymBio Pharmaceuticals after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into SymBio Pharmaceuticals's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)DEPRECIATION (M)DEFERRED TAXES (M)CHANGES IN WORKING CAPITAL (M)NON-CASH ITEM (M)PAID INTEREST (M)PAID TAXES (M)NET CASH FLOW FROM OPERATING ACTIVITIES (B)CAPITAL EXPENDITURES (M)CASH FLOW FROM INVESTING ACTIVITIES (B)CASH FLOW FROM OTHER INVESTING ACTIVITIES (B)INTEREST INCOME AND EXPENSES (M)NET DEBT CHANGE (B)NET CHANGE IN EQUITY (B)CASH FLOW FROM FINANCING ACTIVITIES (B)CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)TOTAL DIVIDENDS PAID (M)NET CHANGE IN CASH FLOW (B)FREE CASH FLOW (M)SHARE-BASED COMPENSATION (M)
200920102011201220132014201520162017201820192020202120222023
-0.21-0.64-2.1-1.73-1.6-1.11-2.63-2.31-3.97-2.75-4.37-4.0912.11-1.2
4688812242529343863939896
000000000000000
-5-137-4926-133-63194-19-54178-245253-1,269-137472
315673549-103137343182211228-353314-438432
000000000000000
2433333333313363354
-0.21-0.75-2.07-1.66-1.68-1.27-2.27-1.96-3.82-2.32-4.35-4.120.141.63-0.19
-3-14-12-30-108-23-27-57-39-216-148-63-47-232
-0-0.12-0.12-0.41-1.330.311.49-0.04-0.08-0.03-0.22-0.16-0.07-0.05-0.38
0-0.1-0.11-0.41-1.330.421.51-0.02-0.020.010-0.01-0.010-0.14
000000000000000
000010.5030000000
2.970.674.6303.070.0400.681.154.283.754.24-0.070.660.69
2.960.664.6104.060.54-03.661.164.273.744.22-0.070.630.68
-8-2-160-90-1-1918-6-11-16-4-32-11
000000000000000
2.75-0.212.4-2.071.05-0.2-0.831.46-2.771.87-0.91-0.060.012.420.23
-214.7-768.2-2,086.5-1,661.6-1,677.3-1,374.8-2,295.47-1,988-3,873.82-2,364.32-4,567.25-4,271.4176.211,580.32-427.48
000000000000000

SymBio Pharmaceuticals stock margins

The SymBio Pharmaceuticals margin analysis displays the gross margin, EBIT margin, as well as the profit margin of SymBio Pharmaceuticals. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for SymBio Pharmaceuticals.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the SymBio Pharmaceuticals's sales revenue. A higher gross margin percentage indicates that the SymBio Pharmaceuticals retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the SymBio Pharmaceuticals's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the SymBio Pharmaceuticals's total revenue generated. When comparing the revenue margin year over year, investors can gauge the SymBio Pharmaceuticals's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the SymBio Pharmaceuticals. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the SymBio Pharmaceuticals's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

SymBio Pharmaceuticals Margin History

SymBio Pharmaceuticals Gross marginSymBio Pharmaceuticals Profit marginSymBio Pharmaceuticals EBIT marginSymBio Pharmaceuticals Profit margin
2026e78.91 %0 %20.37 %
2025e78.91 %0 %17.51 %
2024e78.91 %0 %15.86 %
202378.91 %-14.52 %-35.11 %
202275.94 %19.62 %11.78 %
202170.25 %12.3 %24.61 %
202029.02 %-150.86 %-136.93 %
201930.47 %-151.59 %-154.22 %
201830.58 %-69.25 %-71.76 %
201729.94 %-114.6 %-115.49 %
201638.18 %-89.82 %-97.68 %
201530.16 %-131.99 %-136.15 %
201426.94 %-66.66 %-57.08 %
201320.76 %-109.69 %-104.77 %
201230.33 %-86.96 %-88.65 %
2011-52.1 %-109.8 %-111.79 %
201083.57 %-42.26 %-44.3 %
2009100 %-17.46 %-18.29 %
2008100 %8.15 %1.29 %
200778.91 %0 %0 %
200678.91 %0 %0 %

SymBio Pharmaceuticals Stock Sales Revenue, EBIT, Earnings per Share

The SymBio Pharmaceuticals earnings per share therefore indicates how much revenue SymBio Pharmaceuticals has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SymBio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SymBio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SymBio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SymBio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SymBio Pharmaceuticals Revenue, EBIT and net profit per share

DateSymBio Pharmaceuticals Sales per ShareSymBio Pharmaceuticals EBIT per shareSymBio Pharmaceuticals Earnings per Share
2026e308.51 undefined0 undefined62.85 undefined
2025e301.37 undefined0 undefined52.77 undefined
2024e282.14 undefined0 undefined44.74 undefined
2023140.09 undefined-20.34 undefined-49.19 undefined
2022252.7 undefined49.58 undefined29.77 undefined
2021212.59 undefined26.16 undefined52.32 undefined
202090.65 undefined-136.76 undefined-124.13 undefined
2019122.58 undefined-185.81 undefined-189.03 undefined
2018230.67 undefined-159.74 undefined-165.54 undefined
2017276.32 undefined-316.66 undefined-319.14 undefined
2016240.85 undefined-216.33 undefined-235.27 undefined
2015238.74 undefined-315.11 undefined-325.04 undefined
2014253.9 undefined-169.25 undefined-144.92 undefined
2013264.16 undefined-289.74 undefined-276.76 undefined
2012407.33 undefined-354.23 undefined-361.1 undefined
2011508.78 undefined-558.62 undefined-568.78 undefined
2010302.08 undefined-127.67 undefined-133.81 undefined
2009248.15 undefined-43.33 undefined-45.4 undefined
2008339.58 undefined27.69 undefined4.38 undefined
20070 undefined-277.4 undefined-276.25 undefined
20060 undefined-147.5 undefined-148.17 undefined

SymBio Pharmaceuticals business model

SymBio Pharmaceuticals Ltd is a company specializing in the development and marketing of medical products. The company, based in Japan, was founded in 2005 and currently employs over 300 employees. SymBio Pharmaceuticals is one of the most popular companies on Eulerpool.com.

SymBio Pharmaceuticals SWOT Analysis

Strengths

SymBio Pharmaceuticals Ltd has several strengths that contribute to its competitive advantage in the pharmaceutical industry. These strengths include:

  • Strong research and development capabilities, enabling the company to develop innovative and effective drugs.
  • A diverse and expanding product portfolio, providing a wide range of treatment options and revenue streams.
  • Established partnerships with key industry players, facilitating collaborations and enhancing market presence.
  • A dedicated and highly skilled workforce, driving the success and growth of the company.
  • A solid financial position, allowing for strategic investments and expansion opportunities.

Weaknesses

Despite its strengths, SymBio Pharmaceuticals Ltd also faces certain weaknesses that need to be addressed to optimize its performance and market position. These weaknesses include:

  • Limited global market presence, primarily focused on specific regions, which may restrict revenue potential.
  • Dependence on a few key products for a significant portion of revenue, making the company vulnerable to market fluctuations.
  • Relatively small scale compared to some industry leaders, potentially impacting economies of scale and cost efficiencies.

Opportunities

SymBio Pharmaceuticals Ltd can capitalize on various opportunities to further enhance its market position and profitability. These opportunities include:

  • Growing demand for innovative pharmaceutical solutions, driven by an increasing global aging population and rising healthcare expenditures.
  • Expansion into untapped international markets, broadening the company's customer base and revenue streams.
  • Advancements in technology and research, opening doors for the development of breakthrough drugs and treatments.
  • Potential mergers and acquisitions, allowing SymBio Pharmaceuticals Ltd to gain access to new products or technologies.

Threats

SymBio Pharmaceuticals Ltd operates in a dynamic and competitive industry, which presents certain threats that may impact its performance and profitability. These threats include:

  • Intense competition from established pharmaceutical companies, requiring continuous innovation and differentiation to maintain market share.
  • Regulatory constraints and approval processes, leading to potential delays and increased costs in the development and commercialization of drugs.
  • Rapidly evolving healthcare policies and reimbursement systems, which may impact product pricing and market access.
  • Patent expirations and generic drug competition, posing challenges to maintaining exclusivity and pricing power for certain products.

SymBio Pharmaceuticals Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

SymBio Pharmaceuticals historical P/E ratio, EBIT, and P/S ratio.

SymBio Pharmaceuticals shares outstanding

The number of shares was SymBio Pharmaceuticals in 2023 — This indicates how many shares 39.902 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue SymBio Pharmaceuticals earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates SymBio Pharmaceuticals's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of SymBio Pharmaceuticals’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating SymBio Pharmaceuticals's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

SymBio Pharmaceuticals Stock splits

In SymBio Pharmaceuticals's history, there have been no stock splits.
Unfortunately, there are currently no price targets and forecasts available for SymBio Pharmaceuticals.

SymBio Pharmaceuticals list of shareholders

%
Name
Stocks
Change
Date
2.57461 % Yoshida (Fuminori)1,179,700012/31/2023
1.33128 % Kuroda (Norihiro)610,000-94,00012/31/2023
0.93844 % Ito (Sukenori)430,000012/31/2023
0.58932 % Nomura Securities Co., Ltd.270,03091,43012/31/2023
0.55866 % SBI Securities Co., Ltd.255,980-132,61512/31/2023
0.49065 % Morgan Stanley MUFG Securities Co., Ltd.224,819224,81912/31/2023
0.39698 % Simplex Asset Management Co., Ltd.181,90031,1003/31/2024
0.13138 % State Street Global Advisors (US)60,200-2002/29/2024
0.07922 % Dimensional Fund Advisors, L.P.36,30003/31/2024
0 % Dimensional Fund Advisors, Ltd.0-6,10010/31/2023
1
2

SymBio Pharmaceuticals Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
Eisai Stock
Eisai
SupplierCustomer0,650,670,350,650,750,23
Astellas Pharma Stock
Astellas Pharma
SupplierCustomer0,60-0,300,21-0,30-0,150,50
Eagle Pharmaceuticals Stock
Eagle Pharmaceuticals
SupplierCustomer0,550,74-0,130,10-0,41-0,06
Chimerix Stock
Chimerix
SupplierCustomer0,430,440,680,680,770,57
Onconova Therapeutics Stock
Onconova Therapeutics
SupplierCustomer0,210,740,200,710,77-0,06
Suzuken Stock
Suzuken
SupplierCustomer0,12-0,47-0,69-0,83-0,37-0,48
Toho Stock
Toho
SupplierCustomer0,03-0,70-0,35-0,70-0,42-0,55
Syneos Health A Stock
Syneos Health A
SupplierCustomer-0,050,750,590,770,210,68
1

Most common questions regarding SymBio Pharmaceuticals

What values and corporate philosophy does SymBio Pharmaceuticals represent?

SymBio Pharmaceuticals Ltd represents values of innovation, collaboration, and patient-centric approach. With a strong corporate philosophy, the company focuses on developing novel therapies to address unmet medical needs. SymBio Pharmaceuticals Ltd believes in fostering strategic partnerships and actively engaging with key stakeholders to drive advancements in healthcare. Their commitment to scientific excellence and dedication to improving patients' lives fuel their mission to develop transformative treatments. As a forward-thinking pharmaceutical company, SymBio Pharmaceuticals Ltd prioritizes the health and well-being of individuals, guided by their core values and corporate philosophy.

In which countries and regions is SymBio Pharmaceuticals primarily present?

SymBio Pharmaceuticals Ltd is primarily present in Japan. As a pharmaceutical company, SymBio focuses on developing and commercializing therapeutics for oncology and autoimmune diseases. Headquartered in Tokyo, Japan, the company has established a strong presence within its domestic market. SymBio Pharmaceuticals Ltd's innovative research and development efforts have led to the introduction of several important drugs in Japan. With a commitment to improving patient care and addressing unmet medical needs, SymBio Pharmaceuticals Ltd continues to expand its reach within the Japanese pharmaceutical industry.

What significant milestones has the company SymBio Pharmaceuticals achieved?

SymBio Pharmaceuticals Ltd has achieved several significant milestones. In recent years, the company received approval for Treakisym, its flagship product which is used in the treatment of non-Hodgkin's lymphoma and other malignant lymphomas. SymBio Pharmaceuticals also successfully entered into licensing and collaboration agreements with renowned companies, expanding its global presence and creating opportunities for further growth. Moreover, the company received device approval for Cutisum, a new formulation of Treakisym, providing patients with an improved treatment option. These milestones demonstrate SymBio Pharmaceuticals' commitment to innovation and its dedication to advancing healthcare solutions for patients worldwide.

What is the history and background of the company SymBio Pharmaceuticals?

SymBio Pharmaceuticals Ltd was established in 2005 and is a biopharmaceutical company based in Japan. The company focuses on the development and commercialization of novel oncology therapeutics. With a strong commitment to research and development, SymBio Pharmaceuticals has successfully launched several products in the oncology field, including bendamustine hydrochloride, which is used in the treatment of non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio Pharmaceuticals leverages its deep expertise in drug development and collaborations with global pharmaceutical companies to advance its pipeline of innovative therapies. The company is dedicated to making a meaningful impact in the healthcare industry by providing effective and safe treatment options for cancer patients.

Who are the main competitors of SymBio Pharmaceuticals in the market?

The main competitors of SymBio Pharmaceuticals Ltd in the market are XYZ Pharmaceuticals and ABC Biotech.

In which industries is SymBio Pharmaceuticals primarily active?

SymBio Pharmaceuticals Ltd is primarily active in the pharmaceutical industry.

What is the business model of SymBio Pharmaceuticals?

The business model of SymBio Pharmaceuticals Ltd is centered around the development and commercialization of innovative therapeutic drugs. Being a specialty pharmaceutical company, SymBio focuses on the research, clinical development, and distribution of pharmaceutical products, particularly in the field of oncology and autoimmune diseases. By leveraging its expertise in drug discovery and strategic partnerships, SymBio aims to bring novel and effective treatments to patients worldwide. With a commitment to addressing unmet medical needs, SymBio Pharmaceuticals Ltd strives to deliver high-quality and differentiated healthcare solutions to improve patients' lives.

What is the P/E ratio of SymBio Pharmaceuticals 2024?

The SymBio Pharmaceuticals P/E ratio is 4.61.

What is the P/S ratio of SymBio Pharmaceuticals 2024?

The SymBio Pharmaceuticals P/S ratio is 0.73.

What is the AlleAktien quality score of SymBio Pharmaceuticals?

The AlleAktien quality score for SymBio Pharmaceuticals is 3/10.

What is the revenue of SymBio Pharmaceuticals 2024?

The expected SymBio Pharmaceuticals revenue is 12.93 B JPY.

How high is the profit of SymBio Pharmaceuticals 2024?

The expected SymBio Pharmaceuticals profit is 2.05 B JPY.

What is the business model of SymBio Pharmaceuticals

SymBio Pharmaceuticals Ltd is a leading, globally active company that focuses on the development, approval, and marketing of innovative pharmaceuticals. The company was founded in Japan in 2005 and now has numerous branches worldwide. The company's business strategy is aimed at providing patients worldwide with access to high-quality therapy options that improve medical practice and enhance patients' quality of life. The company relies on targeted research and development as well as close collaboration with academic institutions, other pharmaceutical companies, and patient groups. SymBio Pharmaceuticals operates in three business areas: Pharma Products, Licensing & Development, and Clinical Trials. Pharma Products: SymBio Pharmaceuticals currently offers four products, all of which are approved in Japan. The company has launched Nipent® (Pentostatin), a medication for the treatment of hairy cell leukemia. Ramucirumab (Cyramza®) and Ibritumomab (Zevalin®) are approved in Japan and used in the field of oncology. Treakisym® is a medication for non-Hodgkin lymphomas and is also marketed in Taiwan. The company is working on adding more products and indications to its portfolio. Licensing & Development: SymBio Pharmaceuticals has extensive experience in licensing active substances and technologies from around the world, as well as in collaborating with partners in drug development. The company offers its customers a wide range of services, from early research to drug approval. Clinical Trials: SymBio Pharmaceuticals has conducted a wide range of clinical trials and has extensive expertise in the field of clinical studies, from Phase I to Phase III. The company works closely with academic institutions, other pharmaceutical companies, and CROs to conduct clinical trials. In recent years, SymBio Pharmaceuticals has pursued a successful growth strategy and expanded its business through strategic partnerships and acquisitions. For example, in 2018, the company acquired a majority stake in a company that produces and markets specialized oncology products. In the same year, SymBio announced plans to establish a new cancer research institute in collaboration with other research institutions. Overall, SymBio Pharmaceuticals believes in the importance of innovation and collaboration to meet the medical needs of patients worldwide. The company remains actively seeking new partnerships and acquisition opportunities to continuously expand its product line and services.

What is the SymBio Pharmaceuticals dividend?

SymBio Pharmaceuticals pays a dividend of 0 JPY distributed over payouts per year.

How often does SymBio Pharmaceuticals pay dividends?

The dividend cannot currently be calculated for SymBio Pharmaceuticals or the company does not pay out a dividend.

What is the SymBio Pharmaceuticals ISIN?

The ISIN of SymBio Pharmaceuticals is JP3383050006.

What is the SymBio Pharmaceuticals WKN?

The WKN of SymBio Pharmaceuticals is A1JMJE.

What is the SymBio Pharmaceuticals ticker?

The ticker of SymBio Pharmaceuticals is 4582.T.

How much dividend does SymBio Pharmaceuticals pay?

Over the past 12 months, SymBio Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, SymBio Pharmaceuticals is expected to pay a dividend of 0 JPY.

What is the dividend yield of SymBio Pharmaceuticals?

The current dividend yield of SymBio Pharmaceuticals is .

When does SymBio Pharmaceuticals pay dividends?

SymBio Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of SymBio Pharmaceuticals?

SymBio Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of SymBio Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 JPY are expected. This corresponds to a dividend yield of 0 %.

In which sector is SymBio Pharmaceuticals located?

SymBio Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von SymBio Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of SymBio Pharmaceuticals from 9/18/2024 amounting to 0 JPY, you needed to have the stock in your portfolio before the ex-date on 9/18/2024.

When did SymBio Pharmaceuticals pay the last dividend?

The last dividend was paid out on 9/18/2024.

What was the dividend of SymBio Pharmaceuticals in the year 2023?

In the year 2023, SymBio Pharmaceuticals distributed 0 JPY as dividends.

In which currency does SymBio Pharmaceuticals pay out the dividend?

The dividends of SymBio Pharmaceuticals are distributed in JPY.

All fundamentals about SymBio Pharmaceuticals

Our stock analysis for SymBio Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of SymBio Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.